Clinical trials in pediatric ALS: a TRICALS feasibility study

References

• The European Parliament and The Council of the European Union. Regulation No 1901/2006 of the European Parliament and of the Council on Medicinal Products for Paediatric Use and Amending Regulation. Off J Eur Union 2006;378:1–19.
   Google Scholar
• Sabatelli M, Madia F, Conte A, Luigetti M, Zollino M, Mancuso I, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology 2008;71:876–81.
   PubMed Web of Science ®Google Scholar
• Gouveia LO, de Carvalho M. Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity? Amyotroph Lateral Scler. 2007;8:323–7.
   PubMed Web of Science ®Google Scholar
• Picher-Martel V, Brunet F, Dupré N, Chrestian N. The occurrence of FUS mutations in pediatric amyotrophic lateral sclerosis: a case report and review of the literature. J Child Neurol. 2020;35:556–62.
   PubMed Web of Science ®Google Scholar
• Finsterer J, Burgunder JM. Recent progress in the genetics of motor neuron disease. Eur J Med Genet. 2014;57:103–12.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chió A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
   PubMed Web of Science ®Google Scholar
• Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: Historical and other observations. Brain. 2012;135:2883–91.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Decision Class Waiver on conditions - granting, review, revocation. 2011. Available at: https://www.ema.europa.eu/en/documents/other/cw/1/2011-ema-decision-19-december-2011-class-waiver-conditions_en.pdf. Accessed December 1, 2020.
   Google Scholar
• European Medicines Agency. Decision Class Waiver on conditions - granting, review, revocation. 2010. Available at: www.ema.europa.eu/en/documents/other/p/63/2010-ema-decision-20-december-2010-class-waiver-conditions_en.pdf. Accessed December 1, 2020.
   Google Scholar
• European Medicines Agency. Summary Report on the review of the list of granted Class Waivers (EMA/PDCO/178231/2015EMA/PDCO). 2015;44(0).
   Google Scholar
• van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:655–61.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Front Degener 2020;1–6.
   PubMed Web of Science ®Google Scholar
• The European Parliament and The Council of the European Union. Guideline on good pharmacovigilance practices (GVP).. 2012;(February):1–47. Available at: http://www.jfda.jo/Download/JPC/TheGoodPharmacovigilancePracticev2.pdf. Accessed 1 December 2020.
   Google Scholar
• Opinion of the Paediatric Committee on the granting of a product-specific waiver EMEA-002403-PIP01-18. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0337/2018-ema-decision-8-october-2018-granting-product-specific-waiver-synthetic-ribonucleic-acid_en.pdf. Accessed August 29, 2020.
   Google Scholar
• European Medicines Agency. Opinion of the Paediatric Committee on the granting of a product-specific waiver and on the refusal of a product- specific waiver EMEA-001748-PIP02-18. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0317/2018-ema-decision-12-september-2018-granting-product-specific-waiver-arimoclomol-citrate-condition_en.pdf. Accessed August 29, 2020.
   Google Scholar
• European Medicines Agency. Opinion of the Paediatric Committee on the refusal of a product-specific waiver EMEA-002469-PIP01-18. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0099/2019-ema-decision-22-march-2019-refusal-product-specific-waiver-pyrimidinyl-aminopyridine-dual_en.pdf. Accessed August 29, 2020.
   Google Scholar
• European Medicines Agency. Opinion of the Paediatric Committee on the granting of a product-specific waiver EMEA-001266-PIP04-19. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0001/2020-ema-decision-3-january-2020-granting-product-specific-waiver-masitinib-mesylate-emea-001266_en.pdf. Accessed August 29, 2020.
   Google Scholar
• Hardiman O, Al-Chalabi A, Brayne C, Beghi E, Van Den Berg LH, Chio A, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88:557–63.
   PubMed Web of Science ®Google Scholar
• The European Parliament and The Council of the European Union. Clinical trials regulation. Off J Eur Union 2014;2014:55–7.
   Google Scholar
• Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis. 2019;14:12.
   PubMed Web of Science ®Google Scholar
• Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18:1–18.
   PubMed Web of Science ®Google Scholar
• Anzelewicz S, Garnier H, Rangaswami A, Czauderna P. Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials. Expert Opin Orphan Drugs. 2017;5:613–21.
   Web of Science ®Google Scholar
• Day S, Jonker AH, Lau LPL, Hilgers RD, Irony I, Larsson K, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018;13:1–9.
   PubMed Web of Science ®Google Scholar
• Hepburn CM, Gilpin A, Autmizguine J, Denburg A, Dupuis LL, Finkelstein Y, et al. Improving paediatric medications: a prescription for Canadian children and youth. Paediatr Child Health. 2019;24:333–9.
   PubMed Web of Science ®Google Scholar
• Saitou H, Nakatani D, Myoui A, Kubota T, Ozono K. Pediatric drug development in Japan: current issues and perspectives. Clin Pediatr Endocrinol. 2020;29:1–7.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. List of diseases for which FDA automatically grants a full waiver of pediatric studies. Available at: https://www.fda.gov/media/101440/download. Accessed December 16, 2021.
   Google Scholar
• Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108–13.
   PubMed Web of Science ®Google Scholar
• Chiò A, Mazzini L, D’Alfonso S, Corrado L, Canosa A, Moglia C, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 2018;91:e635–42.
   PubMed Web of Science ®Google Scholar
• Andersen P, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603–15.
   PubMed Web of Science ®Google Scholar
• Chiò A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 2020;167:107986.
   PubMed Web of Science ®Google Scholar
• Van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915–22.
   PubMed Web of Science ®Google Scholar
• Armon C, Hardiman O. The beginning of precision medicine in ALS? Treatment to fit the genes. Neurology 2017;89:1850–1.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–32.
   PubMed Web of Science ®Google Scholar
• Iannaccone ST, Nelson LL. (2017). Spinal muscular atrophy clinical trials. in Spinal Muscul Atrophy (pp. 423-428)Elsevier Inc.
   Google Scholar